Molecular marker discovery and detection for blinding eye disease

Area of Science:

• Ophthalmology
• Biomedical Engineering
• Molecular Diagnostics

Background:

• Early detection of molecular markers in intraocular fluid is crucial for diagnosing and treating eye diseases.
• Proteomic analysis identified Monocyte Chemoattractant Protein-1 (MCP-1) in aqueous humor as a potential marker for blinding eye conditions.

Purpose of the Study:

• To develop and validate a novel molecular detection technology for MCP-1 in human aqueous humor.
• To assess the technology's sensitivity, specificity, and diagnostic potential for blinding eye diseases.

Main Methods:

• Development of a biolayer interference sensing technology using a sandwich assay for MCP-1 detection.
• Incorporation of automation, high throughput, and real-time monitoring for enhanced analysis.
• Validation in discovery and verification cohorts totaling 168 participants.

Main Results:

• The technology achieved a low detection limit (0.16 pM) and high reliability (R² = 0.995) for MCP-1.
• In the verification phase, it detected blinding eye diseases with 95.0% sensitivity within 30 minutes.
• The technology differentiated between age-related macular degeneration and high myopia cataract with 86.0% specificity.

Conclusions:

• The developed molecular detection technology offers a robust and convenient solution for widespread screening of blinding eye diseases.
• This technology facilitates early discovery and differential diagnosis, potentially improving patient outcomes.
• It represents a valuable tool for advancing ophthalmological diagnostics and interventions.